每经AI快讯，近岸蛋白（SH 688137，收盘价：41.9元）10月13日晚间发布公告称，2025年10月13日， 公司收到股东发来的《关于股份减持结果的告知函》，本次菏泽乔贝、上海普近通过集中竞价交易方式 合计减持公司股份约31万股，占公司总股本比例为0.4476%。本次减持计划已实施完毕。 截至发稿，近岸蛋白市值为29亿元。 每经头条（nbdtoutiao）——AI技术滥用调查：明星可被"一键换装"，"擦边"内容成流量密码，技术防 线为何形同虚设？ （记者 曾健辉） 2024年1至12月份，近岸蛋白的营业收入构成为：生命科学基础研究占比43.35%，体外诊断占比 18.64%，生物药占比16.2%，其他业务占比12.54%，mRNA疫苗药物占比9.27%。 ...

Core Viewpoint - Suzhou Nearshore Protein Technology Co., Ltd. has announced an extension of its share repurchase plan by six months, now set to conclude on April 13, 2026, while other aspects of the repurchase plan remain unchanged [1] Summary by Sections Share Repurchase Plan Overview - On September 26, 2024, the company held its second board meeting and subsequently approved a share repurchase plan during the third extraordinary general meeting of shareholders on October 15, 2024. The plan involves using self-owned funds to repurchase a portion of its issued ordinary shares (A-shares) through centralized bidding on the Shanghai Stock Exchange. The repurchase price will not exceed 30.68 yuan per share, with a total repurchase fund of no less than 10 million yuan and no more than 20 million yuan, to be completed within 12 months from the approval date [2] Reasons for Extending the Repurchase Period - Since the approval of the repurchase plan, the company has actively pursued the repurchase. However, due to various factors such as market conditions, stock price fluctuations, funding arrangements, and trading windows, it is anticipated that the repurchase plan cannot be completed within the original timeframe. The company has decided to extend the repurchase period to maintain long-term sustainable operations and protect the long-term interests of all shareholders [3] Impact on the Company and Decision-Making Process - The extension of the share repurchase period will not have a significant impact on the company's financial status, production operations, or future development. It also does not harm the interests of the company or its shareholders, particularly minority shareholders. On October 13, 2025, the company convened its second board meeting to approve the extension of the repurchase period. Since the third extraordinary general meeting of shareholders in 2024 had already authorized the board to handle related matters, no further shareholder approval is required for this extension [4]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-040 苏州近岸蛋白质科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 | 股东名称 | 菏泽乔贝 | | | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 √否 | 一、减持主体减持前基本情况 1 | | 直接持股 5%以上股东 | □是 | √否 | | --- | --- | --- | --- | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：5%以下股东 | | | | 持股数量 | 795,292股 | | | | 持股比例 | 1.1333% | | | | 当前持股股份来源 | IPO 前取得：795,292股 | | | 股东名称 上海普近 股东身份 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 □是 √否 董事、监事和高级管理人员 □是 √否 其他：5%以下股东 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-041 苏州近岸蛋白质科技股份有限公司 关于延长股份回购实施期限的公告 自 2024 年 10 月 15 日召开 2024 年第三次临时股东大会审议通过回购股份方 案以来，公司积极推动回购股份方案的实施。在实施回购期间，受市场行情、公 司股价波动、资金计划安排、交易窗口期等多重因素的综合影响，预计在原定的 回购期限内，无法完成回购计划。根据《上市公司股份回购规则》《上海证券交 易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司综合考虑行 业竞争态势、公司经营现状以及未来的战略发展及资金使用情况等多重因素后， 从维持公司长期可持续经营能力，维护公司全体股东长远利益等角度出发，公司 拟将原回购方案实施期限延长 6 个月，公司股份回购实施截止日期延期至 2026 年 4 月 13 日止。除回购实施期限延长外，回购方案的其他内容未发生变化。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据《上市公司股份回购规则》《上海证券交易所上市公 ...

南财智讯10月13日电，近岸蛋白公告，公司股东荷泽乔贝和上海普近在2025年7月14日至2025年10月13 日期间，通过集中竞价交易方式合计减持公司股份31.41万股，占公司总股本比例为0.45%，减持总金额 为1531.55万元。荷泽乔贝减持16.20万股，减持比例为0.23%，减持后持股比例为0.90%；上海普近减持 15.22万股，减持比例为0.22%，减持后持股比例为0.16%。此次减持计划已实施完毕。 ...

10月10日，近岸蛋白跌3.19%，成交额2632.64万元。两融数据显示，当日近岸蛋白获融资买入额368.48 万元，融资偿还283.58万元，融资净买入84.90万元。截至10月10日，近岸蛋白融资融券余额合计 7208.14万元。 融资方面，近岸蛋白当日融资买入368.48万元。当前融资余额7208.14万元，占流通市值的5.19%，融资 余额超过近一年60%分位水平，处于较高位。 融券方面，近岸蛋白10月10日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，苏州近岸蛋白质科技股份有限公司位于江苏省苏州市吴江经济技术开发区云创路228号3层,4 层，成立日期2009年9月7日，上市日期2022年9月29日，公司主营业务涉及靶点及因子类蛋白、重组抗 体、酶及试剂的研发、生产、销售，并提供相关技术服务。主营业务收入构成为：靶点及因子类蛋白 58.04%，酶及试剂25.63%，CRO服务11.87%，重组抗体2.67%，其他(补充)1.79%。 截至8月20日，近岸蛋白股东户数6459.00 ...

| 主要会计数据 | 本报告期 | 上年同期 | 本报告期比上 年同期增减 | | --- | --- | --- | --- | | | (1-6月) | | (%) | | 营业收入 | 72, 094, 559. 14 | 59,655, 247. 04 | 20. 85 | | 利润总额 | -28, 917, 895. 14 | -16, 478, 569. 67 | 不适用 | | 归属于上市公司股东的净利润 | -24, 223, 570. 82 | -8.905.793.77 | 不适用 | | 归属于上市公司股东的扣除非经 常性损益的净利润 | -26, 684, 693. 64 | -22.999.228.18 | 不适用 | | 经营活动产生的现金流量净额 | -14. 083. 452. 43 | 23, 298, 251, 95 | -160. 45 | 2024年，公司实现营业收入1.28亿元，同比下降16.73%；归属于上市公司股东的净利润为-5441.63万元，上年同期为1284.36万 元；归属于上市公司股东的扣除非经常性损益的净利润为-7174.86万元，上年同期为-721 ...

| 回购方案首次披露日 | 2024/9/28 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 | 10 | 月 | 15 | 日~2025 | 年 | 10 | 月 14 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 0万股 | | | | | | | | | 累计已回购股数占总股本比例 | 0% | | | | | | | | | 累计已回购金额 | 0万元 | | | | | | | | | 实际回购价格区间 | 0元/股~0元/股 | | | | | | | | 一、回购股份的基本情况 公司于 2024 年 9 月 26 日召开第二届董事会第六次临时会议，并于 2024 年 10 月 15 日召开 2024 年第三 ...

Core Points - On September 29, a total of 25 listed companies had their restricted shares unlocked, with a total market value of approximately 24.818 billion yuan [1] Summary by Category Restricted Share Unlocking - The companies involved in the unlocking of restricted shares include: - Luzhou Laojiao (000568) with 102,700 shares from equity incentive restrictions - East China Pharmaceutical (000963) with 215,000 shares from equity incentive restrictions - Taiyuan Heavy Industry (600169) with 11.6502 million shares from equity incentive restrictions - Jinfat Technology (600143) with 7.406 million shares from equity incentive restrictions - Guotai Junan (601211) with 3.2495 million shares from equity incentive restrictions - Guanglian Da (002410) with 3.2334 million shares from equity incentive restrictions - Ningbo Port (601018) with 3.647 billion shares from A-share issuance to legal person allocation - Zhongjin Environment (300145) with 852,070 shares from equity incentive restrictions - Keli Ke (002782) with 768,000 shares from equity incentive restrictions - Yingjie Electric (300820) with 62,500 shares from equity incentive restrictions - Laobaixing (603883) with 868,400 shares from equity incentive restrictions - Zhaoxun Media (301102) with 218 million shares from extended lock-up period - Zhongjing Technology (003026) with 20,000 shares from equity incentive restrictions - Woge Optoelectronics (603773) with 14.8003 million shares from A-share issuance to original shareholders allocation - Hanrui Cobalt (300618) with 104,670 shares from equity incentive restrictions - Fujilai (301258) with 55.362 million shares from extended lock-up period - Wankai New Materials (301216) with 225 million shares from extended lock-up period - Weiteou (301319) with 29.8 million shares from pre-issue share restrictions - Guanshi Technology (605588) with 19,870 shares from equity incentive restrictions - Sanwang Communication (688618) with 13,500 shares - Xidi Micro (688173) with 771,800 shares - Rendu Biology (688193) with 8.4316 million shares - Jinchang Protein (688137) with 7.145 million shares - Jiao Cheng Ultrasound (688392) with 43.8612 million shares - Aike Saibo (688719) with 824,800 shares [1]

Group 1 - The stock price of Nearshore Protein increased by 5.22% to 43.56 CNY per share, with a trading volume of 23.61 million CNY and a turnover rate of 1.71%, resulting in a total market capitalization of 3.057 billion CNY [1] - Nearshore Protein Technology Co., Ltd. was established on September 7, 2009, and went public on September 29, 2022. The company specializes in the research, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, along with providing related technical services [1] - The revenue composition of Nearshore Protein includes: target and factor proteins (58.04%), enzymes and reagents (25.63%), CRO services (11.87%), recombinant antibodies (2.67%), and other (1.79%) [1] Group 2 - Among the top ten circulating shareholders of Nearshore Protein, a fund under Rongtong Fund holds 500,000 shares, unchanged from the previous period, representing 1.53% of the circulating shares, with an estimated floating profit of approximately 1.08 million CNY [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) was established on December 25, 2014, with a latest scale of 2.074 billion CNY. Year-to-date returns are 18.29%, ranking 4813 out of 8171 in its category, while the one-year return is 38.27%, ranking 4040 out of 8004 [2] Group 3 - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has been in the position for 9 years and 34 days. The total asset scale of the fund is 5.629 billion CNY, with the best return during his tenure being 149.47% and the worst being -18.43% [3]